Beyond established angiogenesis inhibitors, PCa therapies aiming at PSMA (Prostate Specific Membrane Antigen) hold the promise to have a substantial anti-angiogenic effect – due to PSMA ́s abundant expression in tumor vasculature. The gene discussed is FOLH1; the disease is posterior cortical atrophy.